Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Autor: Kerry J. Savage, Steven M. Horwitz, Ranjana Advani, Jacob Haaber Christensen, Eva Domingo-Domenech, Giuseppe Rossi, Franck Morschhauser, Onder Alpdogan, Cheolwon Suh, Kensei Tobinai, Andrei Shustov, Marek Trneny, Sam Yuen, Pier Luigi Zinzani, Lorenz Trümper, Tim Ilidge, Owen A. O’Connor, Barbara Pro, Harry Miao, Veronica Bunn, Keenan Fenton, Michelle Fanale, Markus Puhlmann, Swaminathan Iyer

Publikováno v: Blood Advances. 6:5550-5555

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas, the majority of which have high relapse rates following standard therapy. Despite use of consolidative stem cell transplant (SCT) following frontline t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b02787ddbf580ba2112ede2cb297584
https://doi.org/10.1182/bloodadvances.2020003971

Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume

Autor: Ryan C. Lynch, Stefan K. Alig, Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman, Andrei Shustov, Brian G. Till, Vikram Raghunathan, Yolanda D. Tseng, Hilary Coye, Megan Shelby, Susan Ottemiller, Sarith Keo, Kaitlin Verni, Hongyan Du, Jacquelin Vandermeer, Ashley Gaston, Heather A. Rasmussen, Avanti Gulhane, Delphine Chen, Eric Wayne Dean, Paul S. Martin, Edmond A Marzbani, Jenna M. Voutsinas, Ash A. Alizadeh, Ajay K. Gopal

Publikováno v: Blood. 140:6547-6549

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0eae78ad31c8c477309452b645a82f62
https://doi.org/10.1182/blood-2022-160234

NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020

Autor: Neha, Mehta-Shah, Steven M, Horwitz, Stephen, Ansell, Weiyun Z, Ai, Jeffrey, Barnes, Stefan K, Barta, Mark W, Clemens, Ahmet, Dogan, Kristopher, Fisher, Aaron M, Goodman, Gaurav, Goyal, Joan, Guitart, Ahmad, Halwani, Bradley M, Haverkos, Richard T, Hoppe, Eric, Jacobsen, Deepa, Jagadeesh, Matthew A, Lunning, Amitkumar, Mehta, Elise A, Olsen, Barbara, Pro, Saurabh A, Rajguru, Satish, Shanbhag, Aaron, Shaver, Andrei, Shustov, Lubomir, Sokol, Pallawi, Torka, Carlos, Torres-Cabala, Ryan, Wilcox, Basem M, William, Jasmine, Zain, Mary A, Dwyer, Hema, Sundar, Youn H, Kim

Publikováno v: Journal of the National Comprehensive Cancer Network : JNCCN. 18(5)

Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0939b30a42c78a3ecb3f08f30c2524d0
https://pubmed.ncbi.nlm.nih.gov/32380458

Cutaneous manifestations of angioimmunoblastic T-cell lymphoma

Autor: Sidney, Hoskins, Natalie, Moriarty, Kevin, White, Andrea, Kalus, Andrei, Shustov, Michi M, Shinohara

Publikováno v: Dermatology online journal. 25(7)

Angioimmunoblastic T-cell lymphoma (AITL) is a rare form of non-Hodgkin lymphoma often accompanied by autoimmune and paraneoplastic phenomena. Up to 50% of patients with AITL present with skin manifestations. This case series highlights two cases of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::de6fe33776320702ec26af097ee6fdf7
https://pubmed.ncbi.nlm.nih.gov/31450279

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Autor: Steven Horwitz, Owen A O'Connor, Barbara Pro, Tim Illidge, Michelle Fanale, Ranjana Advani, Nancy L Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo-Domenech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Árpád Illés, Kensei Tobinai, Kunihiro Tsukasaki, Su-Peng Yeh, Andrei Shustov, Andreas Hüttmann, Kerry J Savage, Sam Yuen, Swaminathan Iyer, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Trümper, David Aboulafia, Onder Alpdogan, Kiyoshi Ando, Luca Arcaini, Luca Baldini, Naresh Bellam, Nancy Bartlett, Dina Ben Yehuda, Fabio Benedetti, Peter Borchman, Dominique Bordessoule, Pauline Brice, Javier Briones, Dolores Caballero, Angelo Michele Carella, Hung Chang, June Weon Cheong, Seok-Goo Cho, Ilseung Choi, Sylvain Choquet, Andrei Colita, Angela Giovanna Congui, Francesco D'amore, Nam Dang, Kelly Davison, Sophie de Guibert, Peter de Nully Brown, Vincent Delwail, Judit Demeter, Francesco di Raimondo, Young Rok Do, Eva Domingo, Michael Douvas, Martin Dreyling, Thomas Ernst, Keith Fay, Silvia Fernandez Ferrero, Ian Winchester Flinn, Andres Forero-Torres, Christopher Fox, Jonathan Friedberg, Noriko Fukuhara, Jose Garcia-Marco, Jorge Gayoso Cruz, Jose Gomez Codina, Remy Gressin, Andrew Grigg, Ronit Gurion, Corinne Haioun, Roman Hajek, Mathias Hanel, Kiyohiko Hatake, Robert Hensen, Netanel Horowitz, Andreas Huttmann, Arpad Illes, Kenichi Ishizawa, Miguel Islas-Ohlmayer, Eric Jacobsen, Murali Janakiram, Wojciech Jurczak, Mark Kaminski, Koji Kato, Ilya Kirgner, Ching-Yuan Kuo, Mihaela Cornelia Lazaroiu, Katell Le Du, Jong-Seok Lee, Steven LeGouill, Paul LaRosee, Itai Levi, Brian Link, Herve Maisonneuve, Dai Maruyama, Jiri Mayer, John McCarty, Pam McKay, Yosuke Minami, Heidi Mocikova, Enrica Morra, Javier Munoz, Hirokazu Nagai, Owen O'Connor, Stephen Opat, Ruth Pettengell, Antonio Pezzutto, Michael Pfreundschuh, Andrzej Pluta, PierLuigi Porcu, Hang Quach, Alessandro Rambaldi, William Renwick, Ruben Reyes, Antonia Rodriguez Izquierdo, Jia Ruan, Chiara Rusconi, Gilles Salles, Armando Santoro, Jose Sarriera, Kerry Savage, Hirohiko Shibayama, Cheolwon Suh, Anna Sureda, Mitsune Tanimoto, Masafumi Taniwaki, Herve Tilly, Marek Trneny, Lorenz Trumper, Norifumi Tsukamoto, Umberto Vitolo, Jan Walewski, Eckhart Weidmann, Martin Wilhelm, Mathias Witzens-Harig, Abdulraheem Yacoub, Kazuhito Yamamoto, Sung-Soo Yoon, Hwan Jung Yun, Jasmine Zain

Publikováno v: ECHELON-2 Study Group 2019, ' Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial ', Lancet (London, England), vol. 393, no. 10168, pp. 229-240 . https://doi.org/10.1016/S0140-6736(18)32984-2
Horwitz, S, O'Connor, O A, Pro, B, Illidge, T, Fanale, M, Advani, R, Bartlett, N L, Christensen, J H, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, W S, Feldman, T, Lennard, A, Belada, D, Illés, Á, Tobinai, K, Tsukasaki, K, Yeh, S-P, Shustov, A, Hüttmann, A, Savage, K J, Yuen, S, Iyer, S, Zinzani, P L, Hua, Z, Little, M, Rao, S, Woolery, J, Manley, T, Trümper, L & ECHELON-2 Study Group 2019, ' Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial ', Lancet, vol. 393, no. 10168, pp. 229-240 . https://doi.org/10.1016/S0140-6736(18)32984-2

BACKGROUND: Based on the encouraging activity and manageable safety profile observed in a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36b3b4862c5298b1ae704a6491430a8d
http://hdl.handle.net/20.500.11769/493757